Trial
NCT04543409
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Eosinophilic Esophagitis
Intervention
Benralizumab
Why stopped
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints. Given the lack of clear benefit in this patient population, study has been terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-18